成人恶性胶质瘤治疗市场——增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

成人恶性胶质瘤治疗市场已按疾病类型(多形性胶质母细胞瘤、间变性星形细胞瘤、间变性少突胶质细胞瘤、间变性少突胶质细胞瘤和其他类型的疾病)、治疗(化疗、靶向药物治疗和放射治疗)和地理进行细分。

市场快照

Adult Malignant Glioma Therapeutics Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.6 %
Adult Malignant Glioma Therapeutics Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

迄今为止,开发一种有前途的治疗恶性神经胶质瘤的药物非常困难,在过去几年中,许多有前途的候选药物未能达到预期的测试结果。 

然而,通过各种成像方式诊断胶质瘤和分析其进展的技术进步提高了存活率,从而为快速评估几种管道药物的疗效提供了增强的优势。 

预计北美和欧洲将在预测期内主导全球成人恶性胶质瘤治疗市场,这主要是因为报销范围很大。预计亚太地区市场将在 2020-2025 年间以显着的复合年增长率增长。

根据世界卫生组织的数据,全球每年估计有 245,000 例脑和神经系统肿瘤病例报告。多形性胶质母细胞瘤是这些肿瘤中最常见和最致命的。胶质瘤被归类为罕见病;然而,全球发病率在过去十年中稳步上升。采用高通量筛选和 TCGA 等新型药物发现技术,减少了药物发现的总体时间和药物开发成本。这归因于越来越多的参与者参与了包括神经胶质瘤在内的各种治疗领域的新产品开发和发布。

报告范围

恶性脑肿瘤深入到接受者和提供诊断者的心理。恶性神经胶质瘤是原发性脑肿瘤最常见的亚型,是侵袭性、高度侵袭性和神经破坏性的肿瘤,被认为是人类癌症中最致命的肿瘤之一。

Type of Disease
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types of Disease
Therapy
Chemotherapy
Temozolomide
Bevacizumab
Carmustine
Other Types of Chemotherapy
Targeted Drug Therapy
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Other Monoclonal Antibodies
Radiation Therapy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

多形性胶质母细胞瘤部分预计将在预测期内表现出最快的增长

就类型而言,全球成人恶性胶质瘤治疗市场已分为多形性胶质母细胞瘤、间变性星形细胞瘤、间变性少突胶质细胞瘤、间变性少突星形细胞瘤等。根据 2018 年肿瘤学病例报告,全球报告了约 200 例多形性胶质母细胞瘤病例。因此,该部分可能是预测期内最具吸引力的部分,其次是间变性星形细胞瘤。制造商的密集研发重点、大量患者群体的存在推动了对有效疗法以提高整体生存率的需求,以及快速增加创新新药的管道,这些都归因于该细分市场的高增长。

Adult Malignant Glioma Therapeutics Market Key Trends

北美市场份额最大

由于成人恶性胶质瘤治疗技术的进步,北美有望主导全球市场。然而,近期市场的增长可能取决于中国、日本、印度和韩国等亚洲发展中国家的技术和机遇的综合前景。由于需要负担得起的护理和改善医疗基础设施以帮助早期诊断恶性神经胶质瘤的患者人数相对较高,预计亚太市场的增长率将高于平均水平。

Adult Malignant Glioma Therapeutics Market Growth Rate

竞争格局

该市场的领先供应商正在扩大其在亚洲国家(印度、中国、日本和韩国)的业务,因为这些经济体在该地区神经疾病患病率不断增加的情况下,拥有巨大的神经胶质瘤产品潜力。市场上的主要参与者包括默克公司、F. Hoffmann-La Roche Ltd 和 Bio-Rad Laboratories 等。

主要玩家

  1. Merck & Co. Inc.

  2. F. Hoffmann-La Roche Ltd

  3. Arbour Pharmaceuticals LLC

  4. Bristol-Myers Squibb Company

  5. Bio-Rad Laboratories

Merck & Co. Inc. F. Hoffmann-La Roche Ltd Arbour Pharmaceuticals LLC Bristol-Myers Squibb Company Bio-Rad Laboratories

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Incurable Status of the Disease

      2. 4.2.2 Global Increase in Aging Population

      3. 4.2.3 Increasing Prevalence of Brain Disorders

    3. 4.3 Market Restraints

      1. 4.3.1 Diminishing Preference for Chemotherapy

      2. 4.3.2 Low Approval Rates for Novel Therapeutics for Glioma

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type of Disease

      1. 5.1.1 Glioblastoma Multiforme

      2. 5.1.2 Anaplastic Astrocytoma

      3. 5.1.3 Anaplastic Oligodendroglioma

      4. 5.1.4 Anaplastic Oligoastrocytoma

      5. 5.1.5 Other Types of Disease

    2. 5.2 Therapy

      1. 5.2.1 Chemotherapy

        1. 5.2.1.1 Temozolomide

        2. 5.2.1.2 Bevacizumab

        3. 5.2.1.3 Carmustine

        4. 5.2.1.4 Other Types of Chemotherapy

      2. 5.2.2 Targeted Drug Therapy

        1. 5.2.2.1 Epidermal Growth Factor Receptor (EGFR) Inhibitors

        2. 5.2.2.2 Other Monoclonal Antibodies

      3. 5.2.3 Radiation Therapy

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie, Inc.

      2. 6.1.2 Amgen, Inc.

      3. 6.1.3 Arbor Pharmaceuticals

      4. 6.1.4 Bio Rad Laboratories

      5. 6.1.5 Bristol-Myers Squibb Company

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Pfizer, Inc.

      8. 6.1.8 Sun Pharmaceuticals Ltd

      9. 6.1.9 Merck & Co. Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Adult Malignant Glioma Therapeutics Market market is studied from 2018 - 2026.

The Adult Malignant Glioma Therapeutics Market is growing at a CAGR of 9.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Arbour Pharmaceuticals LLC, Bristol-Myers Squibb Company, Bio-Rad Laboratories are the major companies operating in Adult Malignant Glioma Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!